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Abstract  
Objectives:  In June 2011, the National Institute for Health and Care Excellence (NICE) Decision 
Support Unit published a Technical Support Document (TSD) providing recommendations on survival 
analysis for NICE technology appraisals (TAs). Survival analysis outputs are influential inputs into 
economic models estimating the cost-effectiveness of new cancer treatments. Hence, it is important 
that systematic and justifiable model selection approaches are used. This study investigates the 
extent to which the TSD recommendations have been followed since its publication. 
Methods: We reviewed NICE cancer TAs completed between July 2011 and July 2017. Information 
on survival analyses undertaken and associated critiques for overall survival (OS) and progression-
free survival were extracted from the company submissions, Evidence Review Group (ERG) reports 
and final appraisal determination documents. 
Results: Information was extracted from 58 TAs. Only four (7%) followed all TSD recommendations 
for OS outcomes. The vast majority (91%) compared a range of common parametric models and 
assessed their fit to the data (86%). Only a minority of TAs included an assessment of the shape of 
the hazard function (38%) or proportional hazards assumption (40%). Validation of the extrapolated 
portion of the survival function using external data was attempted in a minority of TAs (40%). 
Extrapolated survival functions were frequently criticised by ERGs (71%).  
Conclusions: Survival analysis within NICE TAs remains sub-optimal, despite publication of the TSD. 
Model selection is not undertaken in a systematic way resulting in inconsistencies between TAs. 
More attention needs to be given to assessing hazard functions and validation of extrapolated 
survival functions. Novel methods not described in the TSD have been used, particularly in the 
context of immuno-oncology, suggesting that an updated TSD may be of value.   
Word count; 275 (max. 275)  
Introduction 
Economic evaluation requires a comparison of the incremental costs and health effects of competing 
interventions. Health effects are typically defined in terms of quality adjusted life-years, which 
involves the analysis of patient time-to-event outcomes such as death and progression-free survival 
in oncology. In order to avoid delays in obtaining marketing authorisation and reimbursement 
approval, and because it is usually impractical to run trials with an indefinite length, the timeframe 
of trials is often shorter than the desired time horizon for economic evaluation. In these cases it is 
necessary to extrapolate survival functions beyond the duration of a trial. Different assumptions 
about, and approaches to modelling, the underlying hazard function and resulting survival function 
can affect the estimates of population mean benefit and incremental cost-effectiveness ratios 
(ICERs),[1, 2, 3] particularly when there is a high proportion of unobserved events.[3] Consequently, 
demonstrating that appropriate survival models have been selected is important as this increases 
the likelihood that good funding decisions are made.  
Extrapolation of hazard and survival functions is particularly relevant in the context of cancer health 
technology assessments (HTAs) because a proportion of overall survival (OS) events are often 
censored (i.e. have not yet been observed) at the end of trial follow-up. In the context of cancer 
HTAs, we require an estimate of the population mean survival over a time horizon that captures all 
differences in health benefit, which is usually lifetime. [4, 5, 6, 7, 8] In order to adopt a lifetime 
perspective, assumptions must be made about the hazard and survival functions beyond the 
collection of sample data.  
There are many approaches that can be taken to extrapolate hazard and survival functions. 
Commonly, parametric models are fitted to the sample data to provide a lifetime extrapolation. 
However, model selection should not depend only on the goodness-of-fit of the model to the sample 
data but also on the clinical plausibility of the extrapolated hazard and survival functions. Different 
models can provide very different extrapolated hazard and survival functions, and it is essential that 
the model is selected carefully to ensure that the cost effectiveness analysis (CEA) is based upon a 
plausible estimate of population mean survival. 
Within England the National Institute for Health and Care Excellence (NICE) conducts technology 
appraisals (TAs) and provides guidance to the National Health Service. A typical TA involves a 
company submission providing evidence on the clinical and cost-effectiveness of the technology 
appraised. This evidence is assessed by an independent Evidence Review Group (ERG), which 
produces its own report. These reports are considered by the NICE Appraisal Committee, which 
ultimately produces a final appraisal determination (FAD). The FAD document highlights concerns 
about the analysis or methodological shortcomings of the submission and reports the outcome of 
the appraisal. There are three possible outcomes of the FAD: the technology is or is not 
recommended as a treatment option or (for cancer appraisals only) it is recommended for use 
through the Cancer Drugs Fund. The Cancer Drugs Fund is a managed access fund. It is an option 
when both the clinical and cost-effectiveness evidence are too uncertain for a positive 
recommendation, but the technology has the potential to be cost-effective with additional data 
collection. Further details on the process of NICE TAs is available on their website.[9]   
The NICE Decision Support Unit (DSU) published a Technical Support Document (TSD 14) in June 
2011 to address problems with the inconsistency and application of survival analysis methods 
incorporated in TAs.[10] The TSD provided recommendations for choosing the appropriate survival 
modelling approach based on an assessment of the internal and external validity of the extrapolated 
hazard and survival functions. These recommendations intended to improve the quality and 
consistency of survival modelling in NICE submissions. However, it is not clear to what extent these 
recommendations are being followed in submissions to NICE since the TSD was published. 
This paper provides a review of models used to extrapolate hazard and survival functions in NICE 
Cancer TAs which commenced following the publication of the TSD. It aims to determine whether 
the TSD has been followed and has led to an improvement in terms of consistent and systematic 
application of assessments to inform the selection of appropriate survival extrapolation in NICE 
Cancer TAs, and highlight areas where there is need for further progress.  
  
Methods 
The purpose of this review was to identify the number of Single Technology Appraisals (STAs) that 
followed recommendations TSD 14. TSD 14 made recommendations regarding the assessment of 
internal and external validity of survival models, and incorporation of uncertainty into CEA.  
The methods used for the review followed similar reviews of NICE TAs.[10, 11] The scope was 
restricted to completed NICE STAs for cancer treatments which commenced  between 1
st
 July 2011 
and 30
th
 June 2017. STAs that involved company submissions made prior to 1
st
 July 2011 were 
excluded from our review because it would not have been possible for these to follow the TSD 
recommendations. Multiple Technology appraisals (MTAs) were considered to be out of scope 
because those submissions rely on network meta-analysis, which is not directly relevant to TSD 14. 
The STAs that were within scope were identified from the NICE website [9]. Company submissions, 
ERG reports, and FAD documents were available for each STA and were obtained by information 
specialists and stored on a Mendeley online database [12]. When a STA had been updated by a more 
recent appraisal, evidence from both sources was extracted and counted as one submission, to avoid 
double counting.  
A data extraction form was created by the review team to ensure that the necessary information 
was extracted to meet the aims and objectives of the review. Reviewers collected information on 
the compliance of company submissions and assessment group reports with the recommendations 
of the TSD, in terms of the extrapolation of OS and, where available, progression-free survival (PFS).  
Section headings of the data extraction form corresponded to the key recommendations from TSD 
14[10] and align with the headings in Table 1. Information was also extracted on the extrapolation 
approaches used. In addition, information was extracted from ERG reports regarding criticisms of 
the models used to extrapolate hazard and survival functions applied in company submissions and 
regarding alternative approaches suggested or undertaken. From the FAD, issues relating to the 
extrapolation of survival functions that affected the final decision were highlighted. Most of the 
extraction required a binary  ?ǇĞƐ ?ŶŽ ? ƌĞƐƉŽŶƐĞ, although free text was extracted where additional 
detail was thought to be useful.  Further details of the extraction form are provided in the appendix. 
The TAs were divided between 4 reviewers, with each reviewer following the same pre-specified 
process for data extraction as outlined above. Alongside the binary yes/no responses and free text, 
page numbers of the relevant sections in the TA documents were also noted, to support the data 
extraction. All reviewers met after completing two reviews each to ensure that they were extracting 
the information consistently. At the end ?  ? ?й ŽĨ ĞĂĐŚ ƌĞǀŝĞǁĞƌ ?ƐTAs were allocated for second 
review by two other reviewers (i.e. 10% each) to check the quality of the data extraction. Final 
checks of each review were made by the lead reviewer to confirm the accuracy of the data 
extractions.  
Results 
Compliance with TSD recommendations 
There were 58 STAs within the scope of the review.[13-71] The first company submission was 
submitted in October 2011, 4 months after the publication of the TSD. All 58 of the STAs undertook 
an extrapolation of OS, and 47 of the STAs also undertook an extrapolation of PFS. Despite 39 (67%) 
of the STAs referencing TSD 14, only 4 (7%) STAs fully followed all of its recommendations for the 
extrapolation of OS, and none of the TAs fully followed the recommendations for the extrapolation 
of PFS. Table 1 provides a summary of assessments made in relation to each recommendation.    
Table 1: Compliance with TSD 14 recommendations for extrapolation of OS 
  
Number (%) of TAs 
PFS  OS 
N=22 N=25 N=47 N=24 N=34 N=58 
  
Jul 2011-
2014 
Jul 2014-
2017 
Total 
Jul 2011-
2014 
Jul 2014-
2017 
Total 
1) Internal validity 2 (9%) 11 (44%) 13 (28%) 5 (21%) 10 (29%) 15 (26%) 
   1(a)  Assessed shape of the hazard 8 (36%) 13 (52%) 21 (45%) 10 (42%) 12 (35%) 22 (38%) 
   1(b)  Assessed proportional hazards 7 (32%) 13 (52%) 20 (43%) 8 (33%) 15 (44%) 23 (40%) 
   1(c)  Assessed the relative goodness-of-fit using AIC and/or BIC 19 (86%) 23 (92%) 42 (89%) 20 (83%) 30 (88%) 50 (86%) 
   1(d)  Assessed the absolute goodness of fit  16 (73%) 22(88%) 38 (81%) 16 (67%) 29 (85%) 45 (78%)  
2) External validity 2 (9%) 2 (8%) 4 (9%) 4 (17%) 7 (21%) 11 (19%) 
    2(a) Validated extrapolation with external data 3 (14%) 6 (24%) 9 (19%) 8 (33%) 15 (44%) 23 (40%) 
    2(b) Validated extrapolation according to clinical plausibility 7 (32%) 10 (40%) 17 (36%) 9 (38%) 19 (56%) 28 (48%) 
3) Other             
    3(a)Considered structural uncertainty in sensitivity analyses 17 (77%) 19 (76%) 36 (77%) 18 (75%) 24 (71%) 42 (72%) 
OS: overall survival, PFS: progression-free survival, TA: technology appraisal. The internal validity row (1) 
indicates the number (%) of TAs that performed assessments 1(a), 1(b), 1(c) and 1(d). The external validity row 
(2) indicates the number (%) of TAs that validated 2(a) and 2(b) 
Internal validity of OS model fit was fully assessed in 15 (26%) TAs and for PFS model fit in 13 (28%) 
TAs. Full assessment of internal validity included assessing the shape of the hazard function, the 
plausibility of the proportional hazards assumption, and the goodness-of-fit of the model to the 
data. Proportional hazards were assessed for OS in 23 (38%) TAs and for PFS in 20 (43%) TAs. Of 
those that did not assess proportional hazards, 5 (14%) fitted proportional hazard models for OS and 
6 (22%) fitted proportional hazard models for PFS. The shape of the hazard function was formally 
assessed in 22 (38%) TAs for OS and 21 (45%) for PFS. In 50 (86%) of TAs the relative goodness-of-fit 
of different parametric models for OS was assessed using AIC and/or BIC and in 42 (89%) TAs for PFS. 
The absolute goodness-of-fit of the OS to the sample data was assessed through visual inspection or 
using a test of Cox-Snell residuals in 45 (78%) TAs, and in 38 (81%) TAs for PFS. Of these, visual 
inspection was the more commonly used approach.  
With regards to the external validity of extrapolated OS hazard and survival functions, these were 
validated with both external data and using clinical opinion in the company submission in only 11 
(19%) TAs, and in only 4 (9%) TAs in the case of PFS. In 23 (40%) TAs the OS extrapolated hazard and 
survival functions were validated using external data and in 9 (19%) TAs for PFS. Of the company 
submissions that did not use external data to validate extrapolated OS hazard and survival functions, 
there were 2 cases (6%) where the ERG used external data for validation.[50, 72]  In 28 (48%) TAs 
the OS extrapolated hazard and survival functions were validated using clinical opinion and in 17 
(36%) TAs for PFS. Additional assessments of the structural uncertainty about the OS extrapolated 
survival functions was done using sensitivity analyses in 42 (72%) TAs, and in 36 (77%) TAs in the 
case of PFS.  
To assess if adherence to the TSD had improved over time, the TAs were split into two groups based 
on time of company submission (1
st
 July 2011 to 30
th
 June 2014 and 1
st
 July 2014 to 30
th
 June 2017). 
The comparison did not show any overall substantive change in the proportion of submissions that 
adhered to the TSD recommendations. There was an increase in the proportion of TAs that used 
external data to validate the model and also the proportion that validated the model based on 
clinical opinion. More company submissions followed the TSD for the assessment of PFS in the more 
recent period. 
Extrapolation approaches used 
A range of different approaches were used to extrapolate survival functions. In 53 (91%) TAs 
common parametric distributions were used (i.e. exponential, Weibull, gamma, log-normal and log-
logistic, which are members of the generalised gamma distribution family, and the Gompertz 
distribution) to extrapolate OS hazard and survival functions. This was the case with respect to PFS in 
43 (91%) TAs. Another widely-used method (n = 14, 23%) was to model the data using piecewise 
models which split data at change (or cut) points, with extrapolations based on fitting a parametric 
models to a subset of trial data and/or external data.[15, 20, 40, 54, 68] In 10 submissions the 
company employed a specific type of piecewise model, known as a hybrid model, which typically 
split the observed data into two unique time-periods. This uses Kaplan-Meier estimates for the first 
time-period, with a parametric distribution used for both the second time-period and for generating 
extrapolations. The hybrid method was also applied in seven immunotherapy (IO) TAs for 
melanoma,[17, 30, 38, 41, 49, 56, 66] following the precedent for this method set by the first 
immunotherapy treatment assessed by NICE within this tumour type and reviewed by LRiG.[17] 
In three appraisals, where hazard functions were not compatible with commonly used parametric 
models, other more complex parametric models were used to extrapolate hazard and survival 
functions. In TA414, a mixture-cure model was used to account for differences in the hazard for 
different subgroups of patients.[64] Flexible parametric spline-based models were used in TA374 
and TA417 to account for changes in the hazard rate over time that cannot be captured using 
parametric distributions.[ 66, 72]  
ERG critique 
ERGs criticised the resulting extrapolated survival functions in 41 (71%) of the 58 STAs. The ERGs 
identified twenty-three cases where the TSD had been misinterpreted or not followed. These 
included situations where proportional hazards had been assumed but there had been an incorrect 
assessment or no assessment of the plausibility of the assumption,[ 22, 27, 40, 41, 55, 66] and/or 
where the long-term treatment effect was deemed to be overestimated [23, 25, 26, 29, 36, 39, 43, 
54, 56, 57, 61, 63, 65] or the hazard function was not regarded to be clinically plausible.[20, 38, 41, 
45, 69] The proportional hazards assumption was mostly assumed when treatment switching 
adjustment methods had been applied[31, 32, 55, 60], even though it is not a requirement for 
treatment switching methods. The ERG criticised a submission where the company had applied a HR 
to a control group survival function to estimate the experimental group survival function, where the 
base function took the form of an accelerated failure time distribution, including log-normal or 
gamma parametric models.[43]  ERGs also criticised five cases where external data were not used to 
validate the extrapolation,[ 22, 28, 32, 40, 51], three cases where the external data used was 
deemed to be inappropriate,[38, 62, 68] and five cases where an assessment of goodness-of-fit was 
given priority over external validation of the extrapolated hazard and survival functions.[ 30, 31, 39, 
40, 63] In one appraisal, the ERG suggested that there should have been more transparency around 
the elicitation of expert opinion.[33]  
ERGs criticised applications of the hybrid method of extrapolation where change-points had been 
arbitrarily selected rather than based on the shape of the hazard function or when sensitivity to the 
choice of change-point was not assessed.[15, 19, 54, 69, 68]  
The ERGs assessed the sensitivity of ICERs to both alternative parametric models,[15, 26, 51, 52, 53, 
66] and more pessimistic assumptions about treatment effects during the extrapolated period (for 
example, assuming that there is no treatment benefit).[29, 32] ERGs also assessed the impact of 
alternative change-points as the piecewise models and hybrid models have been criticised for 
arbitrary choice of change point which can often influence the ICER. [15, 54, 73]  
FAD considerations 
The FAD documents provided information on the issues of extrapolating hazard and survival 
functions that were raised during the appraisal committee discussions.  Issues relating to the 
extrapolation of survival functions were discussed in 41 (71%) of the 58 STAs. The main areas of 
discussion were the suitability of proportional hazards assumptions (n = 8) [13, 27, 33, 35, 38, 41, 55, 
60], use of the non-parametric Kaplan-Meier estimator rather than parametric survival functions (n = 
6),[ 15, 26, 40, 46, 47, 54] lack of validation with appropriate external data (n = 2),[28, 45] clinical 
plausibility of the extrapolated hazard and survival functions (n = 19),[ 18, 21, 23, 29, 34, 36, 38, 39, 
41, 47, 49, 52, 53, 56, 57, 62, 63, 66, 69] structural uncertainty about the most plausible 
extrapolation (particularly when the duration of follow-up was short relative to patients' lifetime (n = 
3) [21, 42, 65]) and treatment switching (n = 5).[16, 19, 20, 22, 55] Situations where there was little 
or no discussion regarding the extrapolated survival functions occurred when the sensitivity of the 
ICER had been assessed for a range of plausible models,[24] when the survival function was mature 
[15, 26] or in cases when the treatment was dominated.[20, 43]  
Discussion 
Survival models make assumptions about the shape of the underlying hazard function. Therefore, it 
is important to assess the suitability of the model based on what was observed in the trial period 
and clinical knowledge of both the disease process and mechanism of action of the treatment.[74] 
These assessments will also inform what we expect to observe in the longer term. Sometimes, 
consideration of the underlying hazard function associated with different models could lead to some 
models being rejected as implausible before attempting any statistical analysis.[75] For example, if it 
is believed that the underlying hazard function is non-monotonic then survival models with 
monotonic hazard functions such as a Gompertz distribution can be ruled out. Presentation of the 
empirical hazard function provides a useful descriptive summary of the sample data and further aids 
the identification of an appropriate model.[76] Despite the fact that the TSD guidance advocates 
that model selection should be based upon the hazard function, the shape of the empirical hazard 
function was only considered in around 40% of TAs.   
Assuming proportional hazards is a modelling assumption that is convenient for generating a single 
estimate of treatment effect for drug registration purposes.  Although an assumption of proportional 
hazards used in an HTA may be a consequence of using summary statistics generated from a meta-
analysis, assuming proportional hazards when hazards are not proportional will generate biased 
estimates of population mean time-to-event.[77, 78]  The underlying log hazards for each trial arm 
will not generally be parallel and proportional hazards models can often be ruled out. Despite the 
TSD guidance that proportional hazards assumption should be assessed, in some cases the 
assumption was applied without an assessment.  
Statistical criteria can be used to assess absolute and relative goodness-of-fit, but a more important 
consideration is whether the models proposed are clinically plausible (both to the observed data as 
well as during the extrapolation phase). Despite the fact that the TSD recommends external 
validation using data and/or expert opinion, less than half of the TAs validated extrapolation 
approach according to clinical opinion and less than one third of the TAs used external data to 
choose the modelling approach  
The apparent lack of consideration of these issues highlights the need for improvement in this area 
of assessment in NICE TAs.  It is important to note that not all recommendations made in TSD 14 are 
relevant to all HTAs.  For example, it is not necessary to assess whether hazards are proportional if 
there is no intention of making the proportional hazards assumption.  In addition, for newer 
treatments with a novel mechanism of action, there may not be any relevant external sample data 
available with which to externally validate models.   When these two issues (represented in table 1 
as 1b and 2a) were removed from our criteria, 19% of the TAs reviewed followed the remaining 
suggestions made by TSD 14.  
Several ERGs consistently use common parametric models, whereas it is notable that the LRiG ERG 
often use a hybrid approach based on an exponential survival function to extrapolate from a 
specified point in the tail of the Kaplan-Meier survival function. Whenever a piecewise model is 
used, uncertainty in the choice of change-point should be assessed.[79] Both of the modelling 
approaches are consistent with TSD 14, provided - as for any extrapolation - internal and external 
validity has been considered appropriately. However, companies are aware of disparities in the 
approaches taken by different ERGs, and this has been highlighted by companies involved in writing 
submissions to NICE, with a suggestion that this can be problematic.[80]  However, in situations 
when extrapolation is required, it is important to consider alternative approaches to extrapolation, 
and the onus is on the company or ERG involved to justify the plausibility of the predictions.  
In practice, it is possible that none of the commonly used parametric models described in TSD 14 will 
adequately represent expectations about the long-term hazards and those observed during the trial 
period. An observed hazard function, which is by definition an average over individuals, may exhibit 
odd shapes as a consequence of groups of patients with different underlying risk. For instance, strict 
entry criteria to clinical trials often result in a low short-term hazard function, which increases as 
individuals at higher risk experience an event, then decreases as a consequence of long-term 
survivors. In the longer term, the hazard might increase again if there are any extreme long term 
survivors because of age-related mortality. None of the commonly used survival models can 
represent these two turning points, and it is necessary to consider more complex models in these 
circumstances. 
The focus of this manuscript was on compliance with TSD 14. TSD 14 was authored by the DSU which 
has a specific role in supporting the NICE TA programme. Other guides exist that provide 
recommendations for survival analysis and extrapolation within the context of HTA.[79, 81] The 
content of these existing guides is similar.  
Since the publication of TSD 14, more complex survival models have been used in TAs, such as 
flexible parametric spline models and mixture models (including mixture cure models).[64, 66] There 
is some evidence to suggest that some of the more complex survival models are not well-understood 
by stakeholders in the NICE appraisal process. NICE TA483 was completed after the end date for our 
review but in the company submission, the ERG report and in the FAD a spline model with two knots 
was interpreted as implying that there were three heterogeneous subgroups of patients, each with a 
different survival profile that can be expressed as a combination of three survival functions.[82] In 
fact, this description is more akin to a mixture model, whereas a spline-based model simply 
represents a way of modelling a complex hazard function. That is, a spline-based model only 
describes the population (marginalised) hazard function, and cannot be used to make inferences 
about the unobserved hazard function for sub-groups of patients. The current guidance in TSD 14 for 
these more complex survival models is not detailed. Therefore, it may be useful to publish a new TSD 
to provide additional advice to companies, ERG and Appraisal Committee s on these more complex 
models. 
Finally, TSD14 does not specify how parameters in survival models should be estimated and we did 
not extract this information during the review.  However, it is likely that parameters are being 
estimated mostly using maximum likelihood, and that survival functions are generated using these 
estimates as plug-in values.  Frequentist methods only consider sampling variation and do not deal 
with parameter uncertainty.  Maximum likelihood estimates will generally correspond to the 
Bayesian posterior mode, whereas a Bayesian approach would estimate a survival function by taking 
the expectation with respect to the uncertain parameters.  A maximum likelihood approach also 
requires an assumption of asymptotic multivariate normality in order to approximate joint posterior 
distributions with multivariate sampling distributions for use in probabilistic sensitivity analyses 
(which is inherently Bayesian).  Although such approximations may be reasonable in some situations, 
it is precisely in situations when there are few events and limited follow-up with which to estimate 
parameters that the Bayesian approach and the incorporation of external information is important 
to represent genuine uncertainty.  The review did not assess whether the survival model parameter 
uncertainty was correctly incorporated in the economic models as this would be difficult to assess 
without access to the economic models. Indeed, if there is external information used to validate 
extrapolations then it would be reasonable to include this in the analysis in order to strengthen 
inferences.     
Conclusions 
Extrapolation of hazard and survival functions is a complex area. However, making use of clinical 
knowledge of the disease process and mechanism of action of the treatment, and presenting the 
empirical hazard function should provide useful insights into plausible model selection. In general, 
our review has shown that while the majority of NICE cancer TAs assessed the absolute and relative 
goodness-of-fit of common parametric models to the sample data, other aspects such as 
consideration of the underlying hazard function and the use of external data have been given 
relatively little attention. Overall, there is scope for improvement in the application of survival 
analysis methods used in NICE cancer technology appraisals to achieve greater transparency and 
consistency. An improvement could potentially be supported by explicit referencing in the NICE 
methods guide to TSD 14. Future research could investigate into the reasons for non-adherence to 
the TSD. 
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Appendix Table A1: Extraction form section headings 
Company submission OS/PFS 
x Was an assessment made of the empirical hazard(s) based on the observed data and expert clinical 
input, including the log-cumulative hazard/quantile-quantile/other plots? [yes/no, free-text] 
x What distributions and/or statistical models were fitted to the observed data? [free-text] 
x Was an assessment made of the proportional hazards assumption? [yes/no] 
x How was the relative treatment effect modelled? [free-text] 
x Was an assessment made of the absolute goodness-of-fit i.e. interval validity? [yes/no, free-text] 
x Was an assessment made of the relative goodness-of-fit i.e. internal validity? [yes/no, free-text] 
x Was an assessment made of the external validity (i.e. clinical plausibility) of the extrapolations? 
[yes/no] 
x If, Yes, then what was this based on e.g. expert clinical opinion, external data? [free-text] 
x Was any external evidence used in the generation of the survivor functions? [free-text] 
x Was uncertainty accounted for during the observed and unobserved data periods? [yes/no, free-text] 
x Were summary statistics used to estimate survival for one (e.g. mean, median, proportion or a given 
time) or both arms (e.g. hazard ratio)? [yes/no, free-text] 
x What other considerations are relevant in the assessment (e.g. treatment switching)? [yes/no, free-
text] 
x Did the modelling follow the recommendations of the DSU TSD? [yes/no] 
x If no, then in what ways did the modelling differ from the recommendations? [free-text] 
ERG Report OS/PFS 
x What criticisms did the ERG make of the company submission? [free-text] 
x What alternative approaches did they suggest and/or provide? [free-text] 
FAD  
x TA recommendation [free-text] 
x What issues relating to the extrapolation and modelling of the OS/PFS data did the Appraisal 
Committee mention in the FAD that affected the final decision? [free-text] 
x Which distribution and/or statistical model contributed to the Appraisal Committee s most plausible 
estimate of mean life years, mean QALYs and ICER? [free-text] 
 
 
 
